Moderator and faculty are paid consultants of Alcon.
This communication is not affiliated with the official program of the ASCRS Annual Meeting or any of its subsidiaries.
Because of compliance guidelines, spouses and guests are not allowed, unless they are healthcare professionals.
Please note that attendance at this event is limited to US healthcare professionals that are attending the ASCRS Annual Meeting. No hotel accommodations or travel will be covered for this meeting.
Healthcare Professionals from the United States:
As part of Alcon’s commitment to complying with relevant legal & industry requirements, food, beverage, and other transfers of value will be tracked and reported in accordance with Physician Open Payments reporting, commonly referred to as the Sunshine Act.
Additionally, we regret that we may not be able to provide meals for healthcare professionals employed by the government and/or licensed in the state of Vermont. If you have questions, please notify an Alcon representative.
Note: With your registration, you consent to receive important communications from Alcon via email regarding your registration and details about this event.
Your email will not be used for any other purpose. If you no longer wish to receive emails about this event, you must cancel your registration, as emails are only sent to active registrants.
© 2026 Alcon Inc. US-CPR-2600041
Clareon® PanOptix® Pro Trifocal IOLs
IMPORTANT PRODUCT INFORMATION
CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.
INDICATIONS
The Clareon® PanOptix® Pro Trifocal IOLs include Clareon® PanOptix® Pro and Clareon® PanOptix® ProToric and are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. In addition, the Clareon® PanOptix® Pro Toric Trifocal IOL is indicated for the reduction of residual refractive astigmatism.
WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia, and ensure that IOL centration is achieved.
For the Clareon® PanOptix® Pro Toric Trifocal IOLs, the lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation.
Some visual effects may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos, radial lines around point sources of light (starbursts) under nighttime conditions, or glare, as well as other visual symptoms. As with other multifocal IOLs, there is a possibility that visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. A reduction in contrast sensitivity as compared to that expected with a monofocal IOL may be experienced by some patients and may be more prevalent in low lighting conditions. Therefore, patients implanted with multifocal IOLs should exercise caution when driving at night or in poor visibility conditions.
Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning).
As with other multifocal IOLs, patients may need glasses when reading small print or looking at small objects. Posterior capsule opacification (PCO), may significantly affect the vision of patients with multifocal IOLs sooner in its progression than patients with monofocal IOLs. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with the IOLs.
ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions.
© 2024 Alcon Inc. US-CPR-2400009
Important Product Information – Clareon® TruPlus Aspheric Family of Hydrophobic Acrylic
IOLs with the AutonoMe® Automated Pre-loaded Delivery System
CAUTION: Federal law restricts this device to sale by or on the order of a physician.
INDICATION: The Clareon® TruPlus Aspheric Hydrophobic Acrylic IOLs include the Clareon®
TruPlus Aspheric and Clareon® TruPlus Aspheric Toric IOLs and are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. In addition, the Clareon®
Aspheric Toric IOL is indicated to correct pre-existing corneal astigmatism.
WARNINGS/PRECAUTIONS:
The Clareon® TruPlus IOL is intended for implantation in the capsular bag only. Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio: Patients in whom the posterior capsule is ruptured, zonules are damaged, or primary posterior capsulotomy is planned.
Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting the IOL in a patient with any of the conditions described in the Directions for Use.
For the Clareon® TruPlus Aspheric Toric IOLs, rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation.
As with any surgical procedure, there is risk involved. Potential complications accompanying cataract and/or IOL implantation surgery may include, but are not limited to, the following: lens
epithelial cell ongrowth, corneal endothelial cell damage, infection (endophthalmitis), toxic anterior segment syndrome (TASS), retinal detachment, vitritis, cystoid macular edema, corneal
edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon, anterior uveitis, hyphema, pigment dispersion, posterior capsule opacification, transient or persistent glaucoma, and secondary surgical interventions. Secondary surgical interventions include, but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair.
Prior to surgery, prospective patients should be informed of the possible risks and benefits associated with this IOL as well as the risks and benefits associated with cataract surgery. After surgery, physicians should provide an implant card to patients regarding the IOL implanted.
DO NOT re-sterilize the Clareon® TruPlus IOL or the AutonoMe® Delivery System by any method. The device is for single use only.
ATTENTION: Refer to the Directions for Use labeling for a complete list of indications, warnings and precautions
© 2026 Alcon Inc. US-CVT-2600001
UNITY® VCS and CS Important Product Information
Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician.
Indications / Intended Use:
UNITY VCS: The UNITY VCS console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery.
In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures.
UNITY CS: The UNITY CS console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) ophthalmic surgery.
Warnings: Appropriate use of UNITY VCS and CS parameters and accessories is important for successful procedures. The console supports various accessories to perform various surgical procedures. Accessories include handpieces and probes, as well as tips and sleeves when necessary. Different accessories are required for different procedures and operating modes.
Test for adequate irrigation and aspiration flow, reflux, and operation of each accessory prior to entering the eye.
The consumables used in conjunction with ALCON® instrument products constitute a complete surgical system. To avoid the risk of a patient hazard, do not mismatch consumable components or use settings not specifically adjusted for particular consumable component combinations.
AEs/Complications: Inadvertent activation of functions that are intended for priming or tuning accessories while the accessory is in the eye can create a hazardous situation that could result in patient injury. During any ultrasonic procedure, metal particles may result from inadvertent touching of the ultrasonic tip with a second instrument. Another potential source of metal particles resulting from any ultrasonic handpiece may be the result of ultrasonic energy causing micro abrasion of the ultrasonic tip.
ATTENTION: Refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.
© 2026 Alcon Inc. US-CPR-2600041
Alcon's Privacy Policy | Cookie Notice | Terms of Use | Cvent's Privacy Policy | California Resident? Do Not Sell My Personal Information
Alcon Vision, LLC | 6201 South Freeway | Fort Worth, TX 76134
